Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575418 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations
A Phase 1 study of HIV Prevention, sponsored by Ian McGowan.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01575418 is a Phase 1 study of HIV Prevention that has completed, run by Ian McGowan. The registered enrollment target is 9 participants, below the 382-participant average among 32 other HIV Prevention trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01575418, a Phase 1 study of HIV Prevention, has completed, sponsored by Ian McGowan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blinded, randomized, pharmacokinetic and safety study of 3 rectally applied tenofovir microbicide formulations: a vaginal formulation (VF), a reduced glycerin vaginal formulation (RGVF), and a rectal-specific formulation (RF). Nine HIV-negative men will be enrolled. Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
Conditions Studied
Interventions
- DRUG Rectal formulation (RF) of tenofovir 1% gel
- DRUG Vaginal formulation (VF) of tenofovir 1% gel
- DRUG Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel
- RADIATION Radiolabeling of study drugs and semen
Study Locations (1)
Maryland
- Johns Hopkins University, Division of Clinical Pharmacology, Drug Development Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01575418
The ClinicalTrials.gov registry entry for NCT01575418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 32 other HIV Prevention trials with a reported enrollment target (98% lower). The listed sponsor is Ian McGowan, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Prevention appearing as the primary indexed condition, and to 4 interventions - of which Rectal formulation (RF) of tenofovir 1% gel is the first listed.
NCT01575418 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01575418 about?
NCT01575418 is a clinical study titled "An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations". This is a double-blinded, randomized, pharmacokinetic and safety study of 3 rectally applied tenofovir microbicide formulations: a vaginal formulation (VF), a reduced glycerin vaginal formulation (RGVF), and a rectal-specific formulation (RF). Nine HIV-negative men will be enrolled. Each participan...
What is the current status of trial NCT01575418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-03. Estimated completion is 2013-11.
What conditions does trial NCT01575418 study?
This clinical trial studies the following conditions: HIV Prevention.
What interventions are being tested in trial NCT01575418?
The interventions under investigation include: Rectal formulation (RF) of tenofovir 1% gel (DRUG), Vaginal formulation (VF) of tenofovir 1% gel (DRUG), Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel (DRUG), Radiolabeling of study drugs and semen (RADIATION).
Who is sponsoring clinical trial NCT01575418?
This trial is sponsored by Ian McGowan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01575418 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers
RECRUITING · Phase 1
-
In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
COMPLETED · Phase 1
-
Using PrEP, Doing It for Ourselves
RECRUITING · NA
-
Client-Centered Care Coordination for Black Men Who Have Sex With Men
RECRUITING · NA
-
Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals
RECRUITING · NA
-
Intervention to Enhance PrEP Persistence
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.